Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (LSE:0J2O) from Market Perform to Underperform. As of May 7, 2025, the average one-year ...

Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (BIT:1HALO) from Market Perform to Underperform. There are 1,095 funds or institutions ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...

Biogen Inc. (NASDAQ:BIIB – Free Report) – Leerink Partnrs cut their Q1 2025 earnings estimates for Biogen in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

DOWNGRADES ON CMS ACTION: On Tuesday, Leerink analyst David Risinger downgraded Halozyme to Underperform from Market Perform with a price target of $47, down from $63, and Leerink downgraded ...